Individuals who had taken a type of drug commonly used to treat Type 2 diabetes showed abnormalities in the pancreas, including cell proliferation, that may be associated with an increased risk of neuroendocrine tumors, according to a new study by researchers from UCLA and the University of Florida
Performing at such a high level, he felt invincible
Survodutide (BI 456906) is a novel subcutaneous GCGR/GLP-1R dual agonist in development for the treatment of people with type 2 diabetes, obesity and non-alcoholic steatohepatitis (NASH)
Approval for Cardiovascular Risk Reduction Ongoing cardiovascular outcomes trials (CVOT) studies clearly demonstrated that three of the diabetes incretin medications (liraglutide, dulaglutide and semaglutide) and one of the weight loss versions of this class (Wegovy) also reduce cardiovascular disease risk
[55] Additionally, by blockading FOXO transcription factors and NF-B, the drug modulates SASP and upregulates anti-apoptotic proteins (such as Bcl-2), potentially delaying tissue degeneration and offering anti-aging benefits
While it wont deliver the rapid results associated with prescription injections, it may offer a gentler, longer-term approach with fewer side effects
